Global cost pressures and a fast-changing political and regulatory landscape indicate that the pharmaceutical industry is at an inflection point as we head into 2025, as we outline in our recently published 2025 Global Pharma Outlook.

To navigate this increasingly complex environment, manufacturers must fundamentally rethink their models, focusing on long-term value, evidence-based decision-making and strategic collaboration.